William Blair analyst Tim Lugo downgraded Lyra Therapeutics to Market Perform from Outperform after Lyra announced that the company’s Phase 3 ENLIGHTEN 1 trial evaluating LYR-210 for the treatment of chronic rhinosinusitis did not meet its primary endpoint.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LYRA:
- Lyra Therapeutics Reports Topline Results from Phase 3 ENLIGHTEN 1 Trial for LYR-210 in Chronic Rhinosinusitis
- Lyra Therapeutics Navigates High-Stakes Clinical Trials Amid Safety and Efficacy Challenges
- Lyra Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
- Lyra Therapeutics reports Q1 EPS (35c), consensus (26c)
- Lyra Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)